Workflow
Regeneron: Drug Pricing Woes Notwithstanding, Due For A Major Comeback

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?I last covered the Pharma company Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) for Seeking Alpha in February this year , covering 2024 earnings - revenues were up 8%, to $14.2bn, and GAAP net income per diluted ...